Skip to main content

Breast Cancer

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75 percent of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these...

Team identifies key driver of cancer cell death pathway that activates immune cells

Scientists have identified a protein that plays a pivotal role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers.

Novel Compound May Block Certain Forms of Aggressive Cancer

University of Illinois scientists Benita Katzenellenbogen, Swanlund Professor of Molecular & Integrative Physiology, and John Katzenellenbogen, Swanlund Professor of Chemistry, have developed a new compound with efficacy in suppressing tumor initiation, progression, and metastasis of several...

Members of MCB labs earn newly-established fellowships focused on cancer research

The Beckman Institute has announced its 2023 class of six postdoctoral fellows. Fellows are selected in accordance with the core values of the institute: excellence, collaboration, integrity, transdisciplinarity, exploration, and diversity.

Experts boost activity of potential therapeutic target in triple-negative breast cancer

CHAMPAIGN, Ill. — Less than 20% of diagnosed breast cancers are designated “triple-negative,” meaning that the affected tissues lack three types of receptors often found in other breast cancer types, but TNBCs are often aggressive with ...

New therapeutic target identified for triple-negative breast cancer

Breast cancer is categorized into three major subtypes: hormone receptor-positive, HER2-positive, and triple-negative. Although there are targeted therapeutic approaches for the first two, there are limited options for triple negative-breast cancer patients. In a new study, researchers have...

Meet MCB: Molecular & Integrative Physiology PhD student Hashni Epa Vidana Gamage​

Hashni Epa Vidana Gamage​ is a PhD student in the School of Molecular and Cellular Biology at the University of Illinois Urbana-Champaign. In our latest "Meet MCB" video, Hashni shares what it means to her to be a part of a lab researching ways to improve breast cancer treatment.

Cancer Center at Illinois team finds treatment of liver metastases in breast cancer patients improved by low-carb diets

Urbana, Ill. – A new study by Cancer Center at Illinois Education Program Leader, Zeynep Madak-Erdogan and her team, have found a new mechanism of endocrine resistance in breast cancers metastasized to the liver.

PhD candidate in molecular & integrative physiology named finalist for Research Live! Showcase

A graduate student in the School of Molecular & Cellular Biology competed in the Illinois Graduate College's Research Live! Showcase at the Krannert Center for Performing Arts.

Scientists join together to present findings on impact of lipids on metabolic diseases

The University of Illinois Urbana-Champaign recently hosted the 4th Big Ten Academic Alliance Lipid meeting, bringing together dozens of scientists from across the country to share their expertise on how lipids impact metabolic diseases.